After gains of 6.2% on Friday, Cytokinetics shares are now trading at $93.73. Read below for the essential facts about this stock:
-
Cytokinetics has logged a 121.6% 52 week change, compared to 20.7% for the S&P 500
-
CYTK has an average analyst rating of buy and is 6.64% away from its mean target price of $87.89 per share
-
Its trailing earnings per share (EPS) is $-5.55, which brings its trailing Price to Earnings (P/E) ratio to -16.9. The Health Care sector's average P/E ratio is 30.21
-
The company's forward earnings per share (EPS) is $-4.47 and its forward P/E ratio is -21.0
-
The company's free cash flow for the last fiscal year was $-443030000 and the average free cash flow growth rate is -31.0%
-
Cytokinetics's revenues have an average growth rate of 11.9% with operating expenses growing at 30.2%. The company's current operating margins stand at -6344.4%